JPMorgan Cuts AnaptysBio Price Target to $60.00

JPMorgan Chase & Co. has lowered its price target for AnaptysBio (NASDAQ:ANAB) to $60.00, a 14% reduction from the previous estimate of $70.00. This adjustment was made in a research report issued on Wednesday, with JPMorgan Chase maintaining an 'overweight' rating on the biotechnology company's stock.

The new price target indicates a potential upside of 18.34% from AnaptysBio's previous close. The adjustment is part of ongoing analyst revisions for the company, which has seen its share price fluctuate in recent months.

AnaptysBio's pipeline includes several investigational treatments aimed at cancer and immune-mediated diseases, with a focus on modulating immune-cell signaling. Analysts' predictions for the stock have been mixed, with some firms issuing 'buy' ratings while others recommend holding or selling shares.